MaxiVAX
MaxiVAX is a Swiss clinical-stage biotechnology company.
MaxiVAX has raised €4.6M across 1 funding round, most recently a Series B round in Oct 2019. Based in Geneva, Switzerland; founded 2014; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€4.6M
€4,609,569
Funding rounds
1
Investors
0
distinct backers
Active since
2019-10
latest 2019-10
Funding by year
EUR raised per yearMaxiVAX — funding by year — interactive chart.
Data table
| MaxiVAX — funding by year | |
|---|---|
| 2019 | €4.6M |
Signals
Medium confidenceRaise-next likelihood10
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2019-10-01 | Series B | €4.6M | — | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData